(19)
(11) EP 2 115 140 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.01.2017 Bulletin 2017/04

(45) Mention of the grant of the patent:
30.11.2016 Bulletin 2016/48

(21) Application number: 07705747.9

(22) Date of filing: 31.01.2007
(51) International Patent Classification (IPC): 
C07D 471/04(2006.01)
A61P 31/18(2006.01)
C12N 15/29(2006.01)
C12N 15/10(2006.01)
 A61K 31/437(2006.01)
A61P 35/00(2006.01)
C12N 15/09(2006.01)
(86) International application number:
PCT/IB2007/050322
(87) International publication number:
WO 2008/093173 (07.08.2008 Gazette 2008/32)

(54)

Positively charged water-soluble prodrugs of 1H-imidazo[4,5-c]quinolin-4-amines and related compounds with very high skin penetration rates

Positiv geladene wasserlösliche Arzneistoffvorstufen von 1H-Imidazo-[4,5-c]-chinolin-4-aminen und verwandten Verbindungen mit sehr hohen Hautdurchdringungsgeschwindigkeiten

Promédicaments hydrosolubles à charge positive de 1H-imidazo[4,5-c]quinolin-4-amines et composés associés a taux éléves de pénétration cutanée

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(43) Date of publication of application:
11.11.2009 Bulletin 2009/46

(60) Divisional application:
16200797.5

(73) Proprietor: Yu, Chongxi
Kensington, MD 20895 (US)

(72) Inventor:
  • Yu, Chongxi
    Kensington, MD 20895 (US)

(74) Representative: Finnegan Europe LLP 
16 Old Bailey
London EC4M 7EG
London EC4M 7EG (GB)


(56) References cited: : 
US-A- 4 689 338
 US-A- 4 698 348
   
  • GOBLYOS A. ET AL.: 'Structure-Activity Relationships of New 1H-Imidazo[4,5-c]quinolin-4-amines Derivatives as Allosteric Enhancers of the A3 Adenosine Receptor' J. MED. CHEM. vol. 49, 15 April 2006, pages 3354 - 3361, XP008115094
  • JOHN F.G. ET AL.: 'Structure-Activity Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production' J. MED. CHEM. vol. 48, 21 April 2005, pages 3481 - 3491, XP008115095
  • MARK J.B. ET AL.: '(1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxad iazol-3-ylamine derivatives: Further optimization as highly potent and selective MSK-1-inhibitors' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 15, 20 May 2005, pages 3407 - 3411, XP025314186
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).